Background: Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain and alterations in bowel habits. Three subtypes are defined on the basis of stool patterns: diarrhea-predominant IBS, constipation-predominant IBS, and alternating or mixed IBS. Objectives: To develop patient-reported outcome measures for qualification by the Food and Drug Administration to support product approvals and labeling in IBS; the article focuses on the qualitative research that provided the foundation for the new measures. Methods: Forty-nine concept elicitation and 42 cognitive debriefing interviews were conducted with subjects meeting Rome III criteria; additional criteria were imposed to yield a sample representative of the target patient population. Results: Although incomplete bowel movements, abnormal stool frequency and consistency, and abdominal pain, discomfort, and bloating were reported most frequently across concept elicitation interviews, the relative importance of specific symptoms varied by subtype. Among their five symptoms most important to treat, diarrhea-predominant and alternating or mixed IBS subjects frequently identified urgency, loose/watery stools, abdominal pain, and cramping, whereas constipation-predominant IBS subjects commonly included infrequent and incomplete bowel movements, bloating, and abdominal pain. The cognitive debriefing interviews facilitated refinement of each item set, supported minor modifications following translatability assessment, and suggested improvements to the electronic interface. Furthermore, subjects reported that every item was relevant and no concepts of importance were missing. Conclusions: Results support the content validity of the IBS patient-reported outcome measures. A pilot study was recently initiated to inform item reduction, develop scoring algorithms, and provide preliminary psychometric information. Comprehensive psychometric evaluation and responder definition development will follow.
Introduction
In 2008, the Critical Path Institute, a private, nonprofit organization, established the Patient-Reported Outcome (PRO) Consortium in conjunction with the US Food and Drug Administration (FDA) and the pharmaceutical industry [1] . Concurrently, FDA's Center for Drug Evaluation and Research was advancing a program to provide a pathway for qualifying drug development tools for use in multiple programs to support product approval and labeling claims [2] . To achieve qualification, the center encouraged the creation of collaborative groups (e.g., consortia) to increase efficiency and share resources because of the substantial effort involved. The PRO Consortium is a public-private partnership involving the FDA, the pharmaceutical industry, consulting organizations, academia, and patient advocacy groups that facilitates collaborative, precompetitive development of PRO measures intended for qualification by the FDA.
One of the PRO Consortium's first areas of focus was the assessment of treatment benefit in irritable bowel syndrome (IBS). IBS is a chronic, oftentimes disabling gastrointestinal (GI) disorder characterized by abdominal pain associated with alterations in bowel habits (diarrhea and/or constipation). Although not required for diagnosis, additional bothersome symptoms such as urgency, straining, bloating, incomplete evacuation, and abdominal discomfort are commonly experienced. With a prevalence of 10% to 15%, IBS is one of the most common GI disorders seen by primary care physicians and gastroenterologists [3] . Three subtypes of IBS have been defined on the basis of stool
patterns: diarrhea-predominant IBS (IBS-D), constipationpredominant IBS (IBS-C), and alternating or mixed IBS (IBS-M).
Because a reliable biomarker has not been identified, symptom severity and treatment response in clinical trials must be assessed through PRO measures.
Although global and symptom-specific PRO measures have been used to support approval of treatments for IBS [4] , the FDA has encouraged the development of comprehensive subtypespecific symptom severity measures that meet the expectations described in its PRO guidance [5] . The FDA provided a path forward for IBS drugs presently in development by describing endpoints for IBS-C and IBS-D trials in its IBS guidance [6] ; this document, however, also refers to the current effort: "Once qualified, these IBS subtype-specific PRO measures will replace the provisional endpoints described in this guidance as the FDA's recommended measures of treatment benefit for use in IBS-C and IBS-D clinical trials" [6, p. 11] .
Since 2010, the PRO Consortium's IBS Working Group (IBS WG)-including representatives from Allergan plc (formerly, Forest Research Institute), Ironwood Pharmaceuticals, and Takeda Pharmaceuticals; three academic experts in IBS; and a patient advocate-has been collaborating with RTI Health Solutions to develop PRO measures for each of the three IBS subtypes. Consistent with FDA's IBS guidance, the target patient population for future clinical trials in IBS includes adult males and females meeting Rome III diagnostic criteria and experiencing active symptoms, including a clinically significant level of abdominal pain, and excludes individuals with previous surgeries, other disorders, or taking medications known to affect GI motility. It is anticipated that patients' responses to the PRO measures will be used to generate primary and key secondary efficacy endpoints in clinical trials of new treatments to support product approval and labeling.
The development of the IBS PRO measures has proceeded in accordance with both the PRO guidance and a scoping-stage summary document previously reviewed by FDA's qualification review team. Specifically, a comprehensive literature and instrument review was first conducted to identify symptoms associated with each subtype and how these symptoms had been measured in previous clinical studies. The review of 81 studies involved the identification, description, and/or rating of IBS symptoms by patients, including qualitative, survey, and observational studies. Results revealed that symptoms assessed most commonly included those relevant to all three IBS subtypes: abdominal pain and/or discomfort, abdominal bloating, abnormal stool frequency, and abnormal stool form/consistency. The description and/or assessment of symptoms beyond this core set was dependent on the IBS subtype under study. For example, urgency and straining were featured prominently among studies involving patients with IBS-D and IBS-C, respectively.
An expert panel, including four clinical and/or measurement experts, was also assembled to provide input and supplement the expertise of IBS WG members. Before seeing the results of the literature and instrument review, each clinician on the expert panel provided a list of symptoms he or she deemed important for measurement within each IBS subtype; the results of this exercise closely mirrored those of the literature review.
Although these preliminary efforts identified concepts likely to be important for assessment in future trials, patient input is paramount in PRO measure development. As such, this article focuses on two phases of qualitative research conducted with patients with IBS-concept elicitation (CE) and cognitive debriefing (CD) interviews-to inform both the development of the initial item pools and the subsequent refinement of the three PRO measures: the Diary of Irritable Bowel Syndrome Symptoms -Constipation (DIBSS-C), the DIBSS-Diarrhea (DIBSS-D), and the DIBSS-Mixed (DIBSS-M). Additional inputs, including further guidance from the expert panel, as well as translatability and electronic device usability assessments, are also summarized briefly.
Methods

Subjects
Subjects were recruited through gastroenterology clinics in six US regions and needed to meet the following criteria for participation in the CE and CD interviews:
1. male or nonpregnant female (Z18 years); 2. meets Rome III criteria for IBS-C, IBS-D, or IBS-M [7] and was diagnosed 6 months or more before screening; 3. English-speaking, ambulatory, and community-dwelling; and 4. reports an average abdominal pain intensity level of 3 or more on a 0 to 10 scale over the 7 days before screening.
Potential subjects were excluded if they had previous GI surgeries or recent pelvic surgeries, had other GI disorders with overlapping symptoms (e.g., Crohn disease), were taking medications known to affect GI motility, or had a psychological disorder that, in the referring gastroenterologist's opinion, could potentially hinder their ability to comply with study requirements.
Recruitment targets were also imposed to yield a sample representative of participants in IBS clinical trials recently conducted by IBS WG sponsors in terms of age, sex, race, ethnicity, and varied educational levels. This study was approved by RTI International's institutional review board before the recruitment of any subject.
CE Interviews
Each CE interview was conducted using a subtype-specific, semistructured interview guide with three components (conducted in the following order):
1. Spontaneous CE: Open-ended questions were designed to identify all relevant IBS symptoms, the ways in which subjects experience and speak about these symptoms, the relationships among these symptoms, and the most bothersome symptoms among all those identified spontaneously. 2. Probed CE: If not mentioned spontaneously, subjects were asked about other symptoms considered clinically relevant on the basis of expert input and the literature to fully assess the potential relevance and importance of these symptoms. 3. Most important concepts: Subjects were asked to describe how bothered they were by their IBS symptoms, the extent to which these symptoms interfered with their lives, and the five symptoms they would most want an IBS medication to improve.
The results of the CE interviews were reviewed and summarized on the basis of field notes and analysis of interview transcripts, facilitated by the use of ATLAS.ti, version 6.2 Scientific Software Development GmbH; Berlin, Germany. To assess concept saturation (i.e., the point at which no new symptoms of importance are reported), the IBS-D, IBS-C, and IBS-M interviews were each divided into three sequential groups (approximately one-third of the interviews per group), and the number and nature of new concepts reported by subjects in each subsequent group were reviewed to determine whether additional symptoms were being identified.
Concept Selection and Item Generation
Tables summarizing the frequency with which subjects reported concepts during each component of the CE interviews were assembled and provided to the IBS WG and expert panel members for review before a face-to-face meeting during which symptoms meeting the following criteria were collaboratively selected for measurement: 1) directly attributable to IBS (i.e., impacts were excluded); 2) experienced and deemed important to treat by most subjects (within the relevant subtype); and 3) have the potential to respond to treatment within the context of an IBS clinical trial (e.g., 12-week duration).
Draft item pools were then developed for each measure to address the symptoms selected on the basis of the results of the literature review and CE interviews. Multiple items were developed to address each symptom to permit testing of different wording and response scales with subjects in the CD interviews.
CD Interviews
Three iterative rounds of CD interviews were conducted to ensure that the IBS measures addressed the IBS symptoms of the greatest importance to subjects and to optimize question wording and response scales. To target item refinement (because the DIBSS-M is composed of items in both the DIBSS-C and the DIBSS-D), only subjects with IBS-C or IBS-D were included in the first two rounds of interviews; subjects with a diagnosis of any of the three subtypes were included in the third round.
To facilitate use of the measures in multinational trials, a translatability assessment was conducted after the second set of CD interviews. Specifically, a survey research expert, working with a team of native speakers, reviewed the draft items to identify potential translation difficulties and, when appropriate, suggested revisions to facilitate translation into French (Canada), German (Germany), Portuguese (Brazil), Spanish (United States), and Ukrainian (Ukraine). These five languages were chosen to represent the various cultural regions in which clinical trials are commonly conducted by the project sponsors. The cultural appropriateness and clarity of instructions, questions, and response choices were also reviewed. Prototype versions of the IBS diaries were also developed on handheld devices for use in the third round of CD interviews.
In addition to confirming the relevance and ease of response to the final set of items within the IBS-M population, the third set of interviews provided an opportunity 1) to test minor modifications on the basis of the results of translatability assessment, 2) to optimize the usability of electronic (ePRO) versions of the measures, and 3) to explore the amount of improvement in each symptom that subjects would consider meaningful.
Each interview was conducted according to a semistructured interview guide (tailored by subtype and round).
After a few open-ended questions regarding IBS symptoms and related experiences, the interviews followed a standard "think aloud" process. Subjects were asked to read out loud and describe their thought processes as they considered and responded to each Table 1 -CE and CD interviews: Subject characteristics. CD, cognitive debriefing; CE, concept elicitation; IBS-C, irritable bowel syndrome with constipation; IBS-D, irritable bowel syndrome with diarrhea; IBS-M, mixed irritable bowel syndrome. * Average abdominal pain level across the 7 days before screening as reported by subjects on a 0-10 numeric rating scale ranging from "no pain" to the "worst abdominal pain imaginable."
draft item. Interviewers then posed additional questions designed to further elucidate the subject's interpretation of each item and the response process. At the close of each of the first two rounds of interviews, the interviewers asked whether the instrument missed any concepts of importance or included any that seemed irrelevant to subjects. To facilitate the interpretation of changes in scores, interviewers asked subjects in the final round of interviews to describe the symptom improvements required to conclude that an IBS treatment was working; these subjects were also asked to provide feedback on the usability of the ePRO device.
Results
Subjects
Ninety-two subjects with IBS participated in the CE and CD interviews, including 33 with IBS-D, 33 with IBS-C, and 26 with IBS-M. Demographic and clinical characteristics of the study sample are presented in Table 1 .
CE Interviews (N ¼ 49)
The concepts reported by the CE interview subjects were organized into five main categories: bowel symptoms, abdominal symptoms, other GI symptoms or impacts (e.g., nausea and lack of appetite), rectal symptoms or impacts (e.g., rectal pain and hemorrhoids), and other non-GI symptoms or impacts (e.g., fatigue and irritability). Table 2 presents the bowel and abdominal symptoms reported spontaneously or in response to follow-up (probe) questions by at least five subjects. How frequently each symptom was reported as the single most bothersome IBS symptom is shown in parentheses (wherever applicable).
Although subjects described many abdominal symptoms, these symptoms were highly related to each other and differences were often difficult for subjects to articulate. More than 75% of subjects described the concepts of abdominal pain, abdominal discomfort, bloating, cramping, and gas. Symptoms identified by subjects as most bothersome (Table 2) , as well as those included among the five symptoms they would most like to see improve with treatment (see Fig. 1 ), varied substantially by 
Symptom
Frequency of symptom reports (single most bothersome symptom 
IBS subtype. For example, urgency and bloating were most commonly reported as the single most bothersome symptoms by subjects with IBS-D and IBS-C, respectively. Among the five symptoms most important to treat, the bowel symptoms of urgency and loose and watery stools and the abdominal symptoms of abdominal pain and cramping were most commonly included by IBS-D and IBS-M subjects, whereas infrequent and incomplete bowel movements (BM-related symptoms), bloating, and abdominal pain were most commonly included by subjects with IBS-C. Across subtypes, abdominal pain was included in subjects' lists more commonly than any other IBS symptom. Overall, 96% of the bowel symptoms and 100% of the abdominal symptoms identified during the CE interviews were reported within the first two (of three) sets of interviews, providing strong support for concept saturation.
The study focus was the identification of symptoms for inclusion in the new diaries. Although not addressed here, IBS can have profound impacts on patients' quality of life, which were evident during the interviews conducted for this study and have been documented by others in publications pertaining to the development of IBS-specific quality-of-life measures and other patient-based research [8] [9] [10] [11] [12] .
Concept Selection
After careful review of subject data, the expert panel, in collaboration with the IBS WG, made the following key recommendations and decisions:
1. Focus the item pools on bowel and abdominal symptoms of IBS. Of particular significance, rectal symptoms (caused by abnormal stool consistency and/or straining) and accidents (or consequences of urgency) were considered to be outside the scope of measurement. 2. The item pool for IBS-M should be a combination of the items developed for use in IBS-C and IBS-D.
3. The concept of recurrent BMs (i.e., "clusters") should be captured for IBS-D and IBS-M subtypes, most likely on the basis of the timing of BM entries into an ePRO device. 4. Despite being reported by a substantial number of subjects, concepts such as gas, abdominal fullness, and stool size would not be included in any draft item pool, because these concepts were not defined consistently and/or were not sufficiently distinct from other symptoms. For example, subjects with IBS-C and IBS-M said that large stools were problematic only when a stool was hard in consistency, and small stools were problematic only in the context of incomplete BMs. 5. Because cramping in the context of constipation was less salient and distinct from abdominal pain (in comparison with the context of diarrhea), cramping would not be addressed in the IBS-C item pool.
The final sets of concepts chosen by the IBS WG, on the basis of the results of the subject interviews and the input of the expert panel, included the following: 
Item Generation
Multiple items were drafted to address each of the concepts selected for measurement. Anticipating at least daily administration, each of the BM-related items was worded to capture data on a per-BM basis and the abdominal symptom items used a 24-hour recall period.
Items addressing stool frequency (BMs in past 24 hours and the highest number of BMs in any 1-hour period) were developed for testing purposes; it was, however, expected that stool frequency and recurrent BMs ultimately would be captured via realtime ePRO assessment (on the basis of time and date stamping). Because of differences inherent in BM-related symptoms (e.g., stool frequency, stool form, and straining severity), the corresponding items required a number of different response scales.
The original item pool included three questions for each abdominal symptom: the first addressing the severity of the symptom in general terms ("any [abdominal symptom] experienced"), the second addressing the severity of the symptom "on average," and the third addressing the severity of the symptom "at its worst." The general (first) items were tested in round 1 only to identify how subjects naturally reported the severity of these symptoms. Three different response scales, including two 0 to 10 numeric rating scales (NRS) with differing anchors and a five-point verbal rating scale (VRS), were rotated across each of the original abdominal symptom items. Table 3 presents the underlying measurement concepts, recall period, and the type of response scale(s) used for each IBS symptom in the initial item pool (tested in the first round of CD interviews).
Cognitive Debriefing
BM-related items Administration frequency. Although subjects with IBS-C in the first two rounds of interviews were generally confident in their ability to recall the details of each BM across a 24-hour period (because they passed stool so infrequently), some of the subjects with IBS-D were not sure they could accurately report even the number of BMs in the previous 24 hours. To keep the IBS-C and IBS-D measures as consistent as possible, and with the understanding that the frequency of BMs within IBS-C should increase with efficacious treatment, the decision was made to collect bowel symptom data on an event-driven basis (i.e., immediately after each BM) for all versions of the DIBSS. The value of this data capture approach for the BM-related symptoms was confirmed by all subjects during the third round of interviews.
Stool frequency: Defining a bowel movement. Although no round 1 subjects reported difficulty understanding the stool frequency question, there was some variability in the way subjects described the concept of a BM (e.g., minor difference in whether one could have multiple BMs during a single visit to the bathroom). To ensure comparability between and across subjects (in the context of a clinical trial), several definitions were drafted and refined during the remaining interviews.
Stool form/consistency. Subjects commonly indicated that the Bristol Stool Form Scale (BSFS) [13] assessed what one's stool "looked like," including stool shape and size, and that the VRS alternative assessed what the stool "felt like" during stool passage. A few subjects in each interview round reported difficulty in responding to the BSFS (e.g., could not find a picture that matched stool appearance; did not think verbal descriptions always matched the pictures); all subjects reported that the VRS alternative was relevant, clear, and easy to answer. Particularly given the intention to assess stool consistency, an argument could be made that the VRS alternative is preferable. Nevertheless, because a slight majority of subjects preferred the BSFS to the VRS alternative, noting that it enables a more detailed stool description, and the BSFS is commonly used in clinical trials, both items were retained for quantitative evaluation.
Incomplete BMs and straining (IBS-C and IBS-M). The items
addressing incomplete BMs and straining were easily understood and answered by IBS-C (all rounds) and IBS-M (round 3) interview subjects. Although an item addressing BM completeness was also included in the original IBS-D item pool, it was removed after round 1 because this concept was inconsistently interpreted and highly related to the concepts of BM frequency and recurrent BMs in the context of diarrhea. For example, some IBS-D subjects noted feeling "empty" but knew they would soon have other BMs and therefore indicated that the initial BM was incomplete.
Urgency and recurrent BMs (IBS-D and IBS-M). The item
addressing urgency was easily understood and answered by IBS-D (all rounds) and IBS-M (round 3) interview subjects. Additional testing of the item inquiring about the maximum number of BMs within any 1-hour period (rounds 1 and 2) supported the Abdominal symptom items Administration frequency and conceptual distinctions. All subjects found the 24-hour recall period appropriate, and descriptions of the abdominal symptoms were very consistent across all rounds of CD interviews and with the CE interview results. Although the abdominal symptoms were often described as highly related, most (18) of the 23 subjects in rounds 1 and 2 (during which the distinctions among abdominal symptoms were directly queried) reported that each abdominal symptom was distinct enough to warrant individual assessment.
Item alternatives (average and worst). Although subjects were generally able to articulate the conceptual difference between the severity of a symptom at its "worst" and "on average," they typically gave the same or very similar responses to both items in the context of any given symptom. Because subjects consistently interpreted and were able to respond to the items referring to "worst" severity and there was a desire to assess each symptom in a consistent manner, the items referencing "average" symptom severity were eliminated after the round 2 CD interviews.
Response scale alternatives. Because some subjects indicated that using the words "worst possible" to describe a 10 in the NRS sounded more realistic than "worst imaginable," noting they could imagine a level of severity that may not be possible, the latter anchor was eliminated after the round 2 CD interviews.
Choosing between the NRS and VRS was less clear. Although all round 1 and 2 subjects indicated that the options offered by both response scale types were reasonably distinct and covered the full range of abdominal symptom severity, some had strong preferences between these scales, which are presented in Table 4 .
To facilitate ease of response and the computation of an overall abdominal symptom score, use of the same response scale across the abdominal symptom items was desired. Because subjects were able to answer using either response scale type and the NRS is a well-accepted approach for symptom severity assessment and is recommended in FDA's IBS guidance for the measurement of abdominal pain, only the NRS was retained for further testing after the round 2 CD interviews.
Comprehensiveness and treatment response
Subjects consistently reported that every item was relevant and typically indicated that no important concepts were missing. Table 5 provides the frequency with which specific symptoms were mentioned by round 3 subjects when asked to describe the improvements necessary to conclude that an IBS medication was working. All 18 subjects who responded to this question (2 did not provide answers) reported that an improvement in one or more bowel symptoms would be required for them to feel like an IBS medication was working. Most commonly, IBS-C subjects noted the necessity of an increase in BM frequency, whereas IBS-D and IBS-M subjects indicated that a reduction in urgency would be required. Although abdominal symptoms were less of a focus, perhaps because improvements in abdominal symptoms commonly follow improvements in bowel symptoms, 9 of the subjects reported that an improvement in one or more abdominal symptoms would also be needed to conclude that a medication was working.
Additional Item-Refinement Activities
Translatability and ePRO usability assessment
The only substantive modifications based on the translatability assessment pertained to the BSFS (e.g., the word "bowel movement" changed to "stool"; the word "blob" modified to "pieces"). Subjects' interpretations of the items in round 3 were consistent with the previous rounds of interviews. The feedback from round Urgency  0  5  5  10  More frequent BMs  5  0  0  5  Less frequent BMs  0  2  0  2  Normal frequency of BMs  0  0  3  3  Stool consistency  0  2  0  2  Abdominal symptoms  Bloating  3  0  1  4  Cramping  0  1  2  3  Pain  1  0  2  3 Note. The table includes symptoms mentioned by at least two round 3 subjects. Of the additional symptoms included in the IBS measures, a reduction in straining and an increase in the completeness of BMs were each mentioned by one of the IBS-C subjects. BM, bowel movement; CD, cognitive debriefing; IBS, irritable bowel syndrome; IBS-C, IBS with constipation; IBS-D, IBS with diarrhea; IBS-M, mixed IBS. * Two subjects (one IBS-C and one IBS-M) did not provide responses to this question.
3 subjects also led to minor revision of the electronic interface to optimize the usability of the ePRO-enabled measures in future studies.
Study Limitations
Although study subjects are reasonably representative of the IBS clinical trial population in terms of sex, race, ethnicity, age, and education, 92 participants recruited from 6 clinics are unlikely to fully represent this target patient population.
Conclusions
The results of the research activities conducted to date support the content validity of the DIBSS-C, DIBSS-D, and DIBSS-M for the assessment of symptom severity in clinical trials of new treatments for IBS-C, IBS-D, and IBS-M, respectively. This conclusion has been affirmed by the qualification review team's agreement that the evidence presented in a comprehensive briefing document is sufficient to proceed from the qualitative to the quantitative research stage of instrument development. Figure 2 shows a conceptual framework depicting the symptoms addressed within each of the three measures. The next step in the development process is a quantitative pilot study to help inform the following: 1) potential item reduction; 2) optimal scoring algorithms; and 3) selection of the more appropriate stool form/consistency item (between the BSFS and the five-point VRS). In addition, the results of the quantitative pilot study will provide preliminary information about the psychometric performance of each item and any multi-item composites (e.g., abdominal symptom scale) within the three measures, including their reliability and validity.
Following the quantitative pilot study, it is anticipated that the final measures will be included in longitudinal studies, ideally early-phase clinical trials, to permit a comprehensive psychometric evaluation and the development of robust responder definitions. Each primary end point will then be computed on the basis of these subtype-specific responder definitions in future clinical trials.
It is anticipated that each subtype-specific primary end point will be based on overall responder analyses requiring a product to provide benefit in both the abdominal symptoms severity subscale and one or more BM-related symptoms. The results of queries during the third round of interviews (presented in Table 5 ) suggest that an increase in the frequency of complete BMs may be the most appropriate bowel symptom component in IBS-C. This approach has been used successfully in past clinical trials and is at currently recommended in FDA's IBS guidance. Although this document also recommends an improvement in stool consistency as the bowel symptom component of the IBS-D primary end point, interview results suggest that stool consistency is significant to most participants primarily because loose and watery stools are linked to the single most bothersome symptom, urgency. As a result, it is possible that a decrease in the frequency of BMs associated with urgency may be a more appropriate component of a primary end point for IBS-D. The selection of the best bowel symptom component in IBS-M is more complex. One possibility is to measure change toward an ideal, such as one complete BM per day and a lack of urgency. The selection of this component for all three measures will, however, be further informed by the quantitative pilot study, as well as by discussions with the expert panel and the FDA.
